Neurocrine's elagolix meets Phase II endpoints

Neurocrine (NASDAQ:NBIX) said both doses of elagolix met the primary safety endpoint of mean bone mineral density (BMD) and the secondary efficacy endpoints of improvements in pain at six months in th...